• Return to Headlines

Relatively High EV/EBITDA Ratio Detected in Shares of Vertex Pharm in the Biotechnology Industry (VRTX, GHDX, IONS, BMRN, RGEN)

By Amy Schwartz

Below are the three companies in the Biotechnology industry with the highest enterprise value to EBITDA (EV/EBITDA) ratios. EV/EBITDA is an important metric used in valuing comparable companies. It is capital structure neutral and generally the lower the ratio, the more undervalued the company is believed to be.

Vertex Pharm ranks highest with a an EV/EBITDA ratio of 1,181.85. Following is Genomic Health I with a an EV/EBITDA ratio of 470.62. Ionis Pharmaceut ranks third highest with a an EV/EBITDA ratio of 315.50.

Biomarin Pharmac follows with a an EV/EBITDA ratio of 238.50, and Repligen Corp rounds out the top five with a an EV/EBITDA ratio of 148.42.

SmarTrend is monitoring the recent change of momentum in Biomarin Pharmac. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Biomarin Pharmac in search of a potential trend change.

Keywords: highest ev/ebitda ratio vertex pharm genomic health i ionis pharmaceut biomarin pharmac repligen corp

Ticker(s): VRTX GHDX IONS BMRN RGEN